Critical Path Milestones Sample Clauses

Critical Path Milestones. Owner shall achieve each Critical Path Milestone and shall provide CHGE with evidence, reasonably satisfactory to CHGE, of such achievement on or before the applicable deadline specified below. Critical Path Milestone Deadline to achieve Critical Path Milestone File for all material Permits for the Project needed to meet the Contract Capacity Execution of agreement and payment of fee to perform a System Reliability Impact Study (“SRIS”) Receive a completed SRIS Study (or equivalent) accepted by NYISO Operating Committee sufficient to meet the Contract Capacity of the Project Execution of Facilities Study Agreement and payment of fee to join Class Year Interconnection Facilities Study Execute the Interconnection Agreement with Transmission Owner that is suitable to interconnect the Project and ensure deliverability of Contract Capacity Execute purchase order for the energy storage system, inverter(s) and transformer(s) {CHGE Note: To Be Determined Major Equipment} needed to construct the Project at a size sufficient to achieve the Contract Capacity and other performance requirements specified in this Agreement Obtain all material Permits for the Project needed to meet the Contract Capacity Achieve Substantial Completion If Owner fails to achieve a Critical Path Milestone on or before the applicable deadline Owner may cure such failure; provided, that
AutoNDA by SimpleDocs
Critical Path Milestones. The Integrated Master Project Plan shall outline key, critical path milestones, with “Go/No Go” decision criteria (entrance and exit criteria for each phase of the project). This report shall be due within 90 days of contract award. Updates shall be due as requested by the COR or Co-COR.
Critical Path Milestones. Owner shall achieve each Critical Path Milestone and shall provide O&R with evidence, reasonably satisfactory to O&R, of such achievement on or before the applicable deadline specified below.‌ Critical Path Milestones Deadline to Achieve Critical Path Milestone Obtain Site Control Execute agreement and pay fee to perform a System Reliability Impact Study (“SRIS”) File for all material Permits for the Project needed to meet the Contract Capacity Receive a completed SRIS Study (or equivalent) accepted by NYISO Operating Committee sufficient to meet the Contract Capacity of the Project Execute the Facilities Study Agreement and pay fee to join a Class Year Interconnection Facilities Study Complete 90% of the front-end engineering and design of the Project File Office of Technical Certification and Research (“OTCR”) permit applications with appropriate state or municipal agencies (e.g., the Fire Department of New York (“FDNY”) and the New York City Department of Buildings (“DOB”)), as applicable Receive final OTCR approval(s) Critical Path Milestones Deadline to Achieve Critical Path Milestone Execute the Interconnection Agreement with Transmission Owner to interconnect the Project and ensure deliverability of installed capacity equal to the Contract Capacity Execute purchase order for the battery system, inverter(s) and transformer(s) needed to construct the Project at a size sufficient to achieve the Contract Capacity and other performance requirements specified in this Agreement Obtain all Permits for the Project needed to achieve Substantial Completion Achieve Substantial Completion Receive any additional Permits necessary to achieve Commercial Operation, including the final operational permits from DOB and FDNY Final Completion If Owner fails to achieve a Critical Path Milestone on or before the applicable deadline Owner may cure such failure; provided, that
Critical Path Milestones. [To be developed with consideration of each of the work plan requirements submitted by the Developer pursuant to Attachment C to the Public Policy TransmissionReliability Planning Process Manual and presented herein according to the sequence of the critical path. The NYISO anticipates that the Developer’s critical path schedule will include many of the example milestones set forth below and that most of the other example milestones will be included as Advisory Milestones. The composition and sequence of the Critical Path Milestones will differ depending on the Developer’s Transmission Project and schedule.] Advisory Milestones: [To include in Development Schedule other milestones (e.g., periodic project review meetings) that are not determined to be on the critical path, but that will be monitored by the Developer and reported to NYISO.] [Example Milestones:
Critical Path Milestones. The Construction Manager will perform the Services in accordance with the Target Milestones and the Critical Path Milestones set forth in Exhibit C. The Parties may amend the Target Milestones and/or the Critical Path Milestones at any time, and from time to time, upon mutual agreement.
Critical Path Milestones. Owner shall achieve each Critical Path Milestone and shall provide RG&E with evidence, reasonably satisfactory to RG&E, of such achievement on or before the applicable deadline specified below.
Critical Path Milestones. A "Critical Path Milestone" is a project milestone whose achievement is critical to the timely completion of the applicable Phase and/or the System as identified in the Detailed Implementation Workplan. If VENDOR fails or has failed to meet a Critical Path Milestone due solely to a failure of VENDOR, then, in addition to other rights and remedies provided to ICERS herein, including, without limitation, the right to terminate this Agreement if not cured as provided for in Section 20.2, VENDOR shall, at no additional cost to ICERS, provide ICERS with as many additional and appropriate VENDOR personnel as may be required or necessary to meet the Critical Path Milestones, or, if VENDOR has already failed to meet one or more Critical Path Milestones, complete the Critical Path Milestones within a readjusted time frame agreed upon by ICERS and VENDOR.
AutoNDA by SimpleDocs

Related to Critical Path Milestones

  • Development Milestones In addition to its obligations under Paragraph 7.1, LICENSEE specifically commits to achieving the following development milestones in its diligence activities under this AGREEMENT: (a) (b).

  • Commercial Milestones In partial consideration of the rights granted by AstraZeneca to Licensee hereunder, Licensee shall pay to AstraZeneca the following payments, which shall be non-refundable, non-creditable and fully earned upon the first achievement of the applicable milestone event:

  • Milestones Subject to the provisions of the SGIP, the Parties shall agree on milestones for which each Party is responsible and list them in Attachment 4 of this Agreement. A Party’s obligations under this provision may be extended by agreement. If a Party anticipates that it will be unable to meet a milestone for any reason other than a Force Majeure event, it shall immediately notify the other Parties of the reason(s) for not meeting the milestone and (1) propose the earliest reasonable alternate date by which it can attain this and future milestones, and (2) requesting appropriate amendments to Attachment 4. The Party affected by the failure to meet a milestone shall not unreasonably withhold agreement to such an amendment unless it will suffer significant uncompensated economic or operational harm from the delay, (1) attainment of the same milestone has previously been delayed, or (2) it has reason to believe that the delay in meeting the milestone is intentional or unwarranted notwithstanding the circumstances explained by the Party proposing the amendment.

  • Sales Milestones Subject to the terms and conditions set forth in the Agreement, in the event that the Annual Net Sales made by or on behalf of a Selling Entity for all Licensed Products in a given calendar year first exceeds a threshold set forth in the table immediately below, Pyxis shall pay to LCB the following one-time, non-refundable, non-creditable milestone payments. Annual Net Sales Milestone Threshold Payment (US Dollars) [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] In the event that in a given calendar year more than one (1) Annual Net Sales milestone threshold is achieved, Pyxis shall pay to LCB each separate Annual Net Sales milestone payment with respect to each Annual Net Sales milestone threshold that is achieved in such calendar year. Pyxis shall notify LCB in writing upon the first achievement, in respect of a Licensed Product, by or on behalf of Pyxis or its Affiliate or Sublicensee, of each of the Milestones set forth in Section 5.2 (Development Milestones), Section 5.3 (Regulatory Milestones) and Section 5.4 (Sales Milestones) no later than [***] of Pyxis’s knowledge of achievement thereof, and in any event, each of the Milestones set forth in Section 5.4 (Sales Milestones) no later than [***] after the end of the applicable calendar year in which such Milestone is achieved. No later than [***] of receipt of an appropriate invoice from LCB, Pyxis shall pay the applicable payment due upon achievement of the corresponding Milestone Event. Each Milestone Event shall be deemed to be achieved once for all Licensed Products and shall be payable only once.

  • Regulatory Milestones Celgene shall make the following approval milestone payments to Jounce that are set forth below upon the first achievement by or on behalf of Celgene, its Affiliates or Sublicensees of the Regulatory Milestone Events set forth below with respect to the first Co-Co Product that achieves such event. For clarity, each milestone set forth below shall be due and payable one time only (regardless of the number of Co-Co Products to achieve any such Regulatory Milestone Event). CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Regulatory Milestone Event (For the first Co-Co Product that achieves such event) Milestone Payments (in $ millions) [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] For each of Paragraphs (1) - (3) of this Exhibit C-2, the Parties understand and agree that in no event will more than one (1) milestone payment be paid with respect to any specific event triggering a payment under this Jounce Lead Co-Co Agreement.

  • Milestone Event Milestone Payment [***] [***]

  • Development Milestone Payments In partial consideration for the rights and licenses granted to Coya hereunder, within ten days after the first achievement of each milestone event in a given Indication set forth in this Section 5.2 (Development Milestone Payments) with respect to a Product (each, a “Development Milestone Event”) by or on behalf of Coya or any of its Affiliates or Sublicensees, Coya shall provide ARScience Bio written notice to ARScience Bio identifying the Development Milestone Event achieved. Upon receipt of any such notice of first achievement of a Development Milestone Event by Coya or its Affiliates or Sublicensees, ARScience Bio will promptly invoice Coya for the applicable Development Milestone Event and Coya will make a milestone payment to ARScience Bio in the amount set forth in this Section 5.2 (Development Milestone Payments) corresponding to such Development Milestone Event (each, a “Development Milestone Payment”) within 45 days of receipt of such invoice. On an Indication-by-Indication basis, each Development Milestone Payment shall be payable only upon the first achievement of the corresponding Development Milestone Event by a Product, in any given Indication for which the Development Milestone Events have not been previously achieved (each such Indication, a “New Indication”). No amounts shall be due for subsequent or repeated achievements of such Development Milestone Event with respect to the same or different Mono Product or Combination Product, as applicable, in such Indication. Accordingly and for clarity, the Development Milestone Payment shall be paid only once, when first achieved by Coya, an Affiliate or a Sublicensee, but no payment shall be due if the same milestone is subsequently achieved by one of Coya, an Affiliate or a Sublicensee. For clarity, the amounts owed in Column (a) below shall be due for the first Combination Product to achieve the Development Milestone Events in a New Indication and the amounts owned in Column (c) below shall be due for the first Mono Product to achieve the Development Milestone Events in a New Indication. Any Combination Product or Mono Product to achieve the Development Milestone Events in a New Indication after the first achievement of the Development Milestone Events as described in the foregoing sentence will cause the amounts in Column (b) with respect to a Combination Product and Column (d) with respect to a Mono Product to be due and payable by Coya upon each such occurrence. If the first Product to achieve a Development Milestone Event in any Indication is a Combination Product, the amounts in Column (a) below shall be due and payable by Coya. If the next Product to achieve a Development Milestone Event in a New Indication is a Mono Product, the amounts in Column (c) below would be due and payable by Coya; provided, that if such next Product to achieve a Development Milestone Event in a New Indication is a Combination Product, the amounts in Column (b) would be due and payable by Coya. By way of example, if a Combination Product achieves IND Acceptance in ALS, and is the first Product to achieve a Development Milestone Event under this Agreement, [***] will be due and payable by Coya. If subsequently a Mono Product achieves IND Acceptance in ALS, no Development Milestone Payments will be due and payable by Coya under this Agreement. However, if subsequently any Combination Product achieves IND Acceptance in Alzheimer’s disease, [***] would be due and payable by Coya.

  • Commercial Milestone Payments For each Licensed Product, Licensee shall pay Arvinas the following one-time milestone event payments when the aggregate Net Sales of such Licensed Product in one or more particular country(ies) for a given calendar year (“Annual Net Sales”), where such Licensed Product is a Valid Claim Licensed Product at the time of sale in each of such country(ies), first achieves the corresponding threshold as set forth in this Section 6.3.2 below, subject to the terms of this Section 6.3 and the payment provisions in Article 7 below: Commercial Milestone Event Milestone Event Payment (US$)

  • Milestone A principal event specified in the Contract Documents including the Material Completion and Occupancy Date and other events relating to an intermediate completion date or time.

  • Development and Regulatory Milestones With respect to each of the following milestones, Ikaria shall pay BioLineRx the corresponding payment set forth below within [**] days after the achievement by Ikaria, its Affiliates or Licensees of such milestone: MILESTONE PAYMENT

Time is Money Join Law Insider Premium to draft better contracts faster.